Impact of IL-5 Pathway Inhibition on Circulating Eosinophil- and Remodeling-Related Biomarkers in Severe Eosinophilic Asthma Authors: Piotr Damiański, Anna Kumor-Kisielewska, Adam J Białas, Piotr Kuna, Maciej Kupczyk Published: 2026 ABSTRACT PurposeTo assess the effects of IL-5 pathway inhibition with mepolizumab or benralizumab on circulating eosinophil-related and selected remodeling-associated biomarkers in severe eosinophilic asthma (SEA), and to determine whether these profiles differ according to four-component study-defined early clinical remission (ECR) status.Patients and MethodsThis prospective, observational, single-center cohort study included 30 adults with SEA treated with mepolizumab or benralizumab. Clinical assessment, spirometry, and blood sampling were performed at baseline and after 6 months. The primary endpoint was change in circulating biomarker concentrations; secondary endpoints included clinical improvement and ECR rate.ResultsIL-5 pathway inhibition improved asthma control and lung function, with OCS-treated exacerbations occurring in 4 of 30 patients during follow-up. These changes were accompanied by marked reductions in eosinophil-related biomarkers, with median decreases of 95.3% in blood eosinophils, 79.5% in eosinophil-derived neurotoxin, and 32.9% in galectin-10, respectively; false discovery rate (FDR)-adjusted p≤0.003. Significant but smaller decreases were observed in MMP-10, TGF-β1, and TGF-β2, with median reductions of 5.0%, 21.2%, and 10.9%, respectively; FDR-adjusted p≤0.002. No significant group-level changes were observed for eotaxin-1, MMP-9, TIMP-1, fibulin-1, tenascin-C, or periostin. ECR was achieved in 16 of 30 patients (53.3%). Compared with non-ECR patients, those achieving ECR had lower baseline OCS burden and fewer relevant comorbidities, whereas neither baseline biomarker concentrations nor 6-month biomarker changes differed significantly between groups. Exploratory comparisons did not show consistent differences in clinical outcomes or biomarker changes between mepolizumab and benralizumab.ConclusionIL-5 pathway inhibition in SEA was associated with marked suppression of eosinophil-related biomarkers, more selective changes in remodeling-associated mediators, and meaningful clinical benefit after 6 months. Similar biomarker responses in patients with and without ECR should be interpreted cautiously, but suggest that incomplete clinical response may reflect broader disease burden, particularly comorbidities, rather than insufficient suppression of eosinophilic inflammation alone. Introduction Severe eosinophilic asthma is a distinct phenotype characterized by persistent type-2 inflammation, frequent exacerbations, impaired lung function, and substantial exposure to oral corticosteroids (OCS).1 Eosinophils are central to disease pathogenesis and severity, driving not only chronic airway inflammation but also tissue injury, dysregulated repair, and progressive airway remodeling, which results in sustained structural and functional alterations of the airway wall. Accordingly, both eosinophilia and elevated circulating levels of eosinophil granule–derived proteins—including eosinophil-derived neurotoxin (EDN), eosinophil peroxidase (EPX), and Charcot–Leyden crystals (CLC/galectin-10)—are consistently associated with greater disease severity, reduced lung function, and increased exacerbation risk.2–5 At the mechanistic level, activated eosinophils release cytotoxic granule proteins alongside profibrotic mediators, most notably transforming growth factor-β (TGF-β) and matrix metalloproteinases (MMP), thereby reshaping the airway tissue microenvironment. Experimental and in vitro studies demonstrate that eosinophil-derived mediators promote fibroblast activation and extracellular matrix production, including collagen and fibronectin, leading to excessive matrix deposition and structural reorganization, such as increased accumulation of tenascin and fibulin. Interestingly, beyond eosinophil-dependent effects, emerging evidence suggests that interleukin-5 (IL-5) may directly contribute to airway remodeling through IL-5 receptor α (IL-5Rα) expressed on airway epithelial cells and fibroblasts. This indicates that IL-5/IL-5R signaling can modulate remodeling processes in parallel with, and potentially independent of, eosinophil-mediated mechanisms.2,6,7 Biologic therapies targeting key type 2 inflammatory pathways have transformed the management of severe eosinophilic asthma. Inhibition of the interleukin-5 (IL-5) pathway with agents such as mepolizumab and benralizumab results in profound suppression of eosinophilic inflammation and consistent clinical benefits, including reduced exacerbation rates, improved asthma control, and lung function, with greater efficacy observed in patients with higher baseline eosinophil counts.8,9 Beyond clinical outcomes, anti-IL-5 pathway therapies are associated with significant reductions in airway eosinophilia and structural remodeling. These effects include decreased extracellular matrix deposition, reduced sub-basement membrane thickness, diminished airway smooth muscle area and layer thickness, and a lower extent of epithelial damage.10,11, Notably, IL-5Rα blockade with benralizumab has been shown to reduce tissue eosinophils and myofibroblasts, alongside improvements in hyperinflation and airway dysfunction.12 Despite these advances, clinical response to anti-IL-5 therapy remains heterogeneous, and increasing attention has been given to the concept of clinical remission in severe asthma. While some patients achieve sustained symptom control, functional improvement, and exacerbation-free disease, others exhibit partial or incomplete responses despite effective eosinophil depletion.1,8,9 This variability underscores a critical unmet need for tools that can better capture the biological mechanisms underlying differential treatment responses and help distinguish true disease modification from partial inflammatory control.13,14 Circulating biomarkers of eosinophil activity and airway remodeling have demonstrated some utility in assessing asthma severity, predicting exacerbation risk, and monitoring treatment response, supporting their potential role as minimally invasive tools for evaluating disease activity over time. Although blood-based biomarkers provide indirect measures and may not fully reflect localized airway remodeling, they can capture integrated systemic inflammatory and reparative responses to chronic inflammation and biologic therapy.2–5,13,14 Given the heterogeneity of clinical responses to biologic therapy, it remains unclear whether treatment-induced changes in blood biomarkers differ across levels of clinical response. Therefore, the aim of the present study was to assess the effects of IL-5 pathway inhibition with mepolizumab/benralizumab on previously studied circulating biomarkers related to eosinophilic activity and remodeling-associated pathways in patients with SEA. In addition, we sought to determine whether changes in these biomarkers occur across different levels of clinical response and to explore their relationships with functional and clinical outcomes. Materials and Methods Study Design This study was designed as a prospective, observational, single-center cohort study conducted at Barlicki Hospital in Łódź, Poland. Consecutive adult patients with severe eosinophilic asthma who initiated biologic therapy with mepolizumab or benralizumab between 16 May 2023 and 15 May 2025 were enrolled at treatment initiation, in accordance with national reimbursement criteria. The study protocol included a baseline qualification visit (V0) and a predefined follow-up visit after 6 months of biologic therapy (V1), at which clinical outcomes and circulating biomarker concentrations were prospectively assessed. During the treatment period, patients attended scheduled visits for biologic administration and routine clinical evaluation. Mepolizumab and benralizumab were administered according to their approved dosing regimens. During the initial treatment phase, patients were monitored for treatment effectiveness and tolerability and were trained in self-administration. After this period, medication was dispensed for home use, and follow-up assessment was performed after 6 months of treatment. Selected baseline clinical variables—including asthma exacerbations in the preceding 12 months, maintenance oral corticosteroid use (OCS), duration of asthma and severe asthma, smoking status, asthma treatment, and relevant comorbidities—were obtained through structured patient interviews and review of electronic medical records. At baseline, spirometry was performed and venous blood samples were collected for further analyses. Treatment effectiveness was reassessed after 6 months and included evaluation of asthma exacerbation rate, asthma control (ACQ), quality of life (Mini-AQLQ), maintenance OCS use, lung function, and blood biomarkers. Inclusion and Exclusion Criteria Patients were prospectively enrolled at the time of qualification for biologic therapy based on the national reimbursement criteria for severe uncontrolled eosinophilic asthma. Patients with a documented diagnosis of COPD were not included. The reimbursement criteria included all mandatory major criteria and at least two additional minor criteria, as detailed below. Major inclusion criteria comprised (1) a documented blood eosinophil count >350 cells/µL within the preceding 12 months, (2) a history of at least two asthma exacerbations in the previous year requiring OCS, (3) treatment with high-dose inhaled corticosteroids in accordance with GINA recommendations combined with additional controller therapy, (4) non-smoking status, and (5) exclusion of alternative causes of eosinophilia, including hypereosinophilic syndromes and parasitic infections.Minor inclusion criteria included at least two of the following: (1) uncontrolled asthma symptoms defined by an ACQ score >1.5, (2) hospitalization due to asthma exacerbation within the previous 12 months, (3) a history of a life-threatening asthma attack, (4) persistent airflow limitation (pre-bronchodilator FEV1 <80% predicted or daily peak expiratory flow variability >30%), and (5) impaired asthma-related quality of life defined by mini-AQLQ score <5.0. Major inclusion criteria comprised (1) a documented blood eosinophil count >350 cells/µL within the preceding 12 months, (2) a history of at least two asthma exacerbations in the previous year requiring OCS, (3) treatment with high-dose inhaled corticosteroids in accordance with GINA recommendations combined with additional controller therapy, (4) non-smoking status, and (5) exclusion of alternative causes of eosinophilia, including hypereosinophilic syndromes and parasitic infections. Major inclusion criteria comprised (1) a documented blood eosinophil count >350 cells/µL within the preceding 12 months, (2) a history of at least two asthma exacerbations in the previous year requiring OCS, (3) treatment with high-dose inhaled corticosteroids in accordance with GINA recommendations combined with additional controller therapy, (4) non-smoking status, and (5) exclusion of alternative causes of eosinophilia, including hypereosinophilic syndromes and parasitic infections. Minor inclusion criteria included at least two of the following: (1) uncontrolled asthma symptoms defined by an ACQ score >1.5, (2) hospitalization due to asthma exacerbation within the previous 12 months, (3) a history of a life-threatening asthma attack, (4) persistent airflow limitation (pre-bronchodilator FEV1 <80% predicted or daily peak expiratory flow variability >30%), and (5) impaired asthma-related quality of life defined by mini-AQLQ score <5.0. Minor inclusion criteria included at least two of the following: (1) uncontrolled asthma symptoms defined by an ACQ score >1.5, (2) hospitalization due to asthma exacerbation within the previous 12 months, (3) a history of a life-threatening asthma attack, (4) persistent airflow limitation (pre-bronchodilator FEV1 <80% predicted or daily peak expiratory flow variability >30%), and (5) impaired asthma-related quality of life defined by mini-AQLQ score <5.0. To minimise biological and pre-analytical variability in circulating biomarker measurements, additional baseline eligibility criteria were applied. Patients were required to fulfil all of the following conditions: (1) no maintenance OCS within the preceding 6 months; (2) stable background anti-asthmatic treatment for at least 4 weeks prior to study enrolment; (3) no asthma exacerbation requiring OCS within 4 weeks prior to the qualification visit; (4) no clinical or laboratory evidence of acute infection within the same 4-week period. Exclusion criteria included clinically significant liver disease, diagnosed autoimmune disorders, current treatment with systemic immunosuppressive agents, active malignancy, malignancy diagnosed or treated within the previous 5 years. Participants were additionally excluded from the final analysis if they were found not to meet the above eligibility criteria, withdrew informed consent, discontinued biologic therapy prematurely before the scheduled follow-up visit, or had incomplete clinical or laboratory data precluding reliable assessment of ECR or biomarker changes. Clinical Endpoints Primary Endpoint The primary endpoint was the change in circulating eosinophil-related and remodeling-associated biomarker concentrations between baseline (V0) and follow-up (V1) after 6 months of anti–IL-5/IL-5Rα therapy with mepolizumab or benralizumab. Key Secondary Endpoints Key secondary endpoints included clinical improvement at 6 months, assessed as changes from baseline in asthma exacerbation rate, OCS use, lung function, asthma control, and quality of life, as well as the proportion of patients achieving study-defined ECR at the follow-up visit. Exploratory Endpoints Exploratory endpoints included (1) comparisons of baseline biomarker levels and biomarker changes according to ECR status, (2) comparisons of clinical outcomes and biomarker changes between patients treated with mepolizumab and benralizumab, and (3) correlation analyses between circulating biomarkers and selected clinical variables. Definition of Study-Defined Early Clinical Remission Study-defined ECR was assessed at the follow-up visit as a composite endpoint requiring fulfillment of all of the following criteria: (1) no asthma exacerbations requiring OCS, (2) no asthma-related hospitalizations during the observation period, (3) well-controlled symptoms defined as an ACQ-6 score <1.5, and (4) an improvement in pre-bronchodilator FEV1 of at least 100 mL compared with baseline. Patients fulfilling all criteria were classified as having achieved ECR, whereas those who did not meet all remission criteria were classified as not achieving ECR. For subgroup analyses, patients were categorized into the ECR and non-ECR groups. Sample Collection and Biomarker Measurements All blood samples for biomarker analyses were collected in the morning, after an overnight fast, under standardized conditions. Peripheral venous blood was collected during routine laboratory assessment into Sarstedt clot activator tubes (4.9 mL) for serum preparation and 9NC tubes (2.7 mL) for plasma preparation. Plasma was separated after approximately 10 minutes of standing time and centrifugation for 15 minutes at 1500 rpm. Serum was obtained after clotting for 30–60 minutes at room temperature in an upright position and centrifugation for 15 minutes at 3200 rpm. Serum and plasma samples were then aliquoted (approximately 500 µL per aliquot) and transferred to −80 °C for long-term storage until analysis. Before measurement, frozen samples were thawed gradually at 4 °C, brought to room temperature, gently mixed, and recentrifuged. All samples underwent a single freeze–thaw cycle only, and were not subjected to repeated freeze–thaw procedures. To reduce analytical variability, all samples for a given analyte were analyzed within a single analytical run using the same ELISA plate and kit lot, in accordance with the manufacturers’ instructions. Biomarker concentrations were determined using commercially available ELISA kits. EDN was measured in plasma using the IDK EDN ELISA kit (Immunodiagnostik AG, Germany), whereas galectin-10 (Gal-10), eotaxin-1, MMP-10, MMP-9, TIMP-1, fibulin-1, tenascin-C (TNC), periostin, TGF-β1, and TGF-β2 were measured in serum using ELISA kits from Cloud-Clone Corp. (USA). Absorbance was read using a BioTek ELx800 microplate reader, and concentrations were calculated with KCJunior software. Data Analysis Statistical analyses were performed using R software version 4.4.2 for macOS. Normality of continuous variables was assessed using the Shapiro–Wilk test. Continuous data are presented as mean ± standard deviation (SD) or median [interquartile range (IQR)], as appropriate according to variable distribution. Comparisons between independent groups were performed using the unpaired Student’s t-test or Wilcoxon rank-sum test, as appropriate. Paired comparisons were performed using the Wilcoxon signed-rank test. Categorical variables were compared using Fisher’s exact test because of the small sample size and sparse cell counts in several contingency tables. Given the skewed distribution of several biomarker variables, associations between continuous variables were assessed using Spearman’s rank correlation coefficient. Because multiple biomarkers were evaluated in the overall cohort, p values from the primary biomarker analysis were additionally adjusted using the Benjamini–Hochberg false discovery rate (FDR) procedure. For subgroup analyses according to remission status and biologic type, p values are presented unadjusted and should be interpreted as exploratory. Missing data were not imputed. ECR was analyzed as a secondary endpoint. However, multivariable logistic regression for ECR was not performed because of the limited sample size and the small number of outcome events, in order to avoid model overfitting. Comparisons between mepolizumab and benralizumab were exploratory and should be interpreted as hypothesis-generating. Results Study Population and Baseline Characteristics Thirty patients with severe eosinophilic asthma were included in the final analysis, including 17 treated with mepolizumab and 13 with benralizumab. The mean age of the cohort was 58.0 ± 12.7 years, and 46.7% were male. Patients had long-standing disease, with a median time from asthma diagnosis to SA of 11.5 [7.3–20.5] years and a median duration of SA of 3.0 [2.0–5.0] years. Baseline asthma control was poor, as reflected by a mean ACQ score of 3.09 ± 0.81, and mean pre-bronchodilator FEV1 was 77.3 ± 17.9% predicted. Comorbidities were frequent, most commonly chronic rhinosinusitis with nasal polyps, allergic rhinitis, and obesity. Baseline demographic and clinical characteristics are summarized in Tables 1 and 2.Table 1Study Population and Baseline CharacteristicsVariablesOverall (n=30)Early Clinical Remission (n= 16)No Clinical Remission (n=14)P valueAge, years58.0 ± 12.756.4 ± 10.559.8 ± 15.00.47Male sex14/30 (46.7)7/16 (43.8)7/14 (50.0)1.00Time from asthma diagnosis to SA, years11.5 [7.3–20.5]13 [8–21]9 [4–23]0.64Duration of SA, years3 [2–5]3 [2–4]4.5 [2.25–5.75]0.19BMI, kg/m229.0 ± 5.327.6 ± 4.730.6 ± 5.70.13Former smoker6/30 (20.0)4/16 (25.0)2/14 (14.3)0.66Positive sIgE/SPT to perennial allergens, n (%)11/30 (36.7)8/16 (50.0)3/14 (21.4)0.14Positive sIgE/SPT to seasonal allergens, n (%)8/30 (27.0)6/16 (37.5)2/14 (14.3)0.23Asthma treatment, n/N (%)LABA/ICS23/30 (76.7)14/16 (87.5)9/14 (64.3)0.20LABA/LAMA/ICS7/30 (23.3)2/16 (12.5)5/14 (35.7)0.20LTRA22/30 (73.3)13/16 (81.3)9/14 (64.3)0.42Theophylline1/30 (3.3)0/16 (0.0)1/14 (7.1)0.46Reported comorbidities, n/N (%)Chronic rhinosinusitis without nasal polyps10/30 (33.3)7/16 (43.8)3/14 (21.4)0.26Chronic rhinosinusitis with nasal polyps13/30 (43.3)8/16 (50.0)5/14 (35.7)0.48Previous polypectomy/FESS9/30 (30.0)6/16 (37.5)3/14 (21.4)0.44Allergic rhinitis13/30 (43.3)8/16 (50.0)5/14 (35.7)0.48Chronic heart failure9/30 (30.0)2/16 (12.5)7/14 (50.0)0.046Diabetes mellitus2/30 (6.7)0/16 (0.0)2/14 (14.3)0.21GERD9/30 (30.0)3/16 (18.8)6/14 (42.9)0.24Bronchiectasis2/30 (6.7)0/16 (0.0)2/14 (14.3)0.21Depression2/30 (6.7)0/16 (0.0)2/14 (14.3)0.21Obesity11/30 (36.7)4/16 (25.0)7/14 (50.0)0.26Intolerance to NSAID9/30 (30.0)7/16 (43.8)2/14 (14.3)0.12Number of selected comorbidities affecting asthma control*1 [0–2]0.0 [0.0–1.0]1.5 [0.25–2.75]0.03Notes: Data are presented as mean ± standard deviation, median [interquartile range], or n/N (%), as appropriate. P values refer to comparisons between the early clinical remission and no clinical remission groups. * The number of selected comorbidities affecting asthma control included chronic heart failure, GERD, bronchiectasis, depression, and obesity. Upper airway disease (allergic rhinitis and chronic rhinosinusitis, with or without nasal polyps) was excluded owing to its high prevalence and limited discriminatory value in this cohort.Abbreviations: BMI, body mass index; FESS, functional endoscopic sinus surgery; GERD, gastroesophageal reflux disease; ICS, inhaled corticosteroid; LABA, long-acting β2-agonist; LAMA, long-acting muscarinic antagonist; LTRA, leukotriene receptor antagonist; NSAID, non-steroidal anti-inflammatory drug; SA, severe asthma; sIgE, specific immunoglobulin E; SPT, skin prick test. Table 2Clinical and Spirometric Outcomes According to Early Clinical Remission Status After 6 Months of Biologic TherapyParameterOverall (n=30)Early Clinical Remission (n=16)No Clinical Remission (n=14)p-valueACQ score at baseline3.09 ± 0.812.96 ± 0.643.14 ± 0.930.52Change in ACQ score from baseline−1.75 [−2.20, −1.03]−1.98 [−2.60, −1.78]−1.10 [−1.68, −0.91]0.01Mini-AQLQ score at baseline3.25 ± 1.013.33 ± 1.023.19 ± 0.970.69Change in mini-AQLQ score from baseline2.05 [1.13–2.75]2.15 [1.18–3.05]2.05 [1.08–2.25]0.31Cumulative OCS dose in the year prior to enrollment*1.23 [1.00–2.85]1.00 [0.88–1.34]2.20 [1.21–3.75]0.03Cumulative OCS dose during 6 months after treatment initiation0.00 [0.00–0.00]0.00 [0.00–0.00]0.00 [0.00–1.85]0.01OCS–treated exacerbations (previous year before enrollment)3.0 [2.0–4.0]2.5 [2.0–4.0]3.0 [3.0–4.0]0.12Any OCS-treated exacerbation during follow-up, n (%)4/30 (13.3)0/16 (0.0)4/14 (28.6)0.04Hospitalizations due to exacerbations in the year before enrollment0.0 [0.0–0.0]0 [0.0–0.0]0 [0.0–1.0]0.38Pre-bronchodilator FEV1, (%) predicted77.3 ± 17.980.3 ± 19.173.9 ± 16.50.33Change in pre-bronchodilator FEV1 (%), percentage points5.5 [1.25–19.0]15.0 [8–29]0.5 [−2.5–6.0]<0.01Pre-bronchodilator FEV1, L2.26 ± 0.802.37 ± 0.792.13 ± 0.810.41Change in pre-bronchodilator FEV1, L0.15 [0.04–0.42]0.35 [0.17–0.79]0.01 [−0.11–0.14]<0.001Pre-bronchodilator FVC, % predicted94.3 ± 15.796.4 ± 15.491.9 ± 16.30.66Change in pre-bronchodilator FVC (%), percentage points4.5 [−0.5–21.5]21.0 [4.0–26.3]2.5 [−6.3–9.5]<0.01Pre-bronchodilator FVC, L3.34 ± 0.933.43 ± 0.833.25 ± 1.050.44Change in pre-bronchodilator FVC, L0.15 [−0.02–0.55]0.55 [0.12–1.11]0.02 [−0.18–0.29]<0.01Notes: Data are presented as mean ± standard deviation, median [interquartile range], or n/N (%), as appropriate. P values refer to comparisons between the early clinical remission and no clinical remission groups. * Expressed as mg/day prednisone equivalent, averaged over the 12 months prior to enrollmentAbbreviations: ACQ, Asthma Control Questionnaire; mini-AQLQ, Mini Asthma Quality of Life Questionnaire; FEV1, forced expiratory volume in 1 second; FVC, forced vital capacity; OCS, oral corticosteroids. Table 1Study Population and Baseline CharacteristicsVariablesOverall (n=30)Early Clinical Remission (n= 16)No Clinical Remission (n=14)P valueAge, years58.0 ± 12.756.4 ± 10.559.8 ± 15.00.47Male sex14/30 (46.7)7/16 (43.8)7/14 (50.0)1.00Time from asthma diagnosis to SA, years11.5 [7.3–20.5]13 [8–21]9 [4–23]0.64Duration of SA, years3 [2–5]3 [2–4]4.5 [2.25–5.75]0.19BMI, kg/m229.0 ± 5.327.6 ± 4.730.6 ± 5.70.13Former smoker6/30 (20.0)4/16 (25.0)2/14 (14.3)0.66Positive sIgE/SPT to perennial allergens, n (%)11/30 (36.7)8/16 (50.0)3/14 (21.4)0.14Positive sIgE/SPT to seasonal allergens, n (%)8/30 (27.0)6/16 (37.5)2/14 (14.3)0.23Asthma treatment, n/N (%)LABA/ICS23/30 (76.7)14/16 (87.5)9/14 (64.3)0.20LABA/LAMA/ICS7/30 (23.3)2/16 (12.5)5/14 (35.7)0.20LTRA22/30 (73.3)13/16 (81.3)9/14 (64.3)0.42Theophylline1/30 (3.3)0/16 (0.0)1/14 (7.1)0.46Reported comorbidities, n/N (%)Chronic rhinosinusitis without nasal polyps10/30 (33.3)7/16 (43.8)3/14 (21.4)0.26Chronic rhinosinusitis with nasal polyps13/30 (43.3)8/16 (50.0)5/14 (35.7)0.48Previous polypectomy/FESS9/30 (30.0)6/16 (37.5)3/14 (21.4)0.44Allergic rhinitis13/30 (43.3)8/16 (50.0)5/14 (35.7)0.48Chronic heart failure9/30 (30.0)2/16 (12.5)7/14 (50.0)0.046Diabetes mellitus2/30 (6.7)0/16 (0.0)2/14 (14.3)0.21GERD9/30 (30.0)3/16 (18.8)6/14 (42.9)0.24Bronchiectasis2/30 (6.7)0/16 (0.0)2/14 (14.3)0.21Depression2/30 (6.7)0/16 (0.0)2/14 (14.3)0.21Obesity11/30 (36.7)4/16 (25.0)7/14 (50.0)0.26Intolerance to NSAID9/30 (30.0)7/16 (43.8)2/14 (14.3)0.12Number of selected comorbidities affecting asthma control*1 [0–2]0.0 [0.0–1.0]1.5 [0.25–2.75]0.03Notes: Data are presented as mean ± standard deviation, median [interquartile range], or n/N (%), as appropriate. P values refer to comparisons between the early clinical remission and no clinical remission groups. * The number of selected comorbidities affecting asthma control included chronic heart failure, GERD, bronchiectasis, depression, and obesity. Upper airway disease (allergic rhinitis and chronic rhinosinusitis, with or without nasal polyps) was excluded owing to its high prevalence and limited discriminatory value in this cohort.Abbreviations: BMI, body mass index; FESS, functional endoscopic sinus surgery; GERD, gastroesophageal reflux disease; ICS, inhaled corticosteroid; LABA, long-acting β2-agonist; LAMA, long-acting muscarinic antagonist; LTRA, leukotriene receptor antagonist; NSAID, non-steroidal anti-inflammatory drug; SA, severe asthma; sIgE, specific immunoglobulin E; SPT, skin prick test. Study Population and Baseline Characteristics Notes: Data are presented as mean ± standard deviation, median [interquartile range], or n/N (%), as appropriate. P values refer to comparisons between the early clinical remission and no clinical remission groups. * The number of selected comorbidities affecting asthma control included chronic heart failure, GERD, bronchiectasis, depression, and obesity. Upper airway disease (allergic rhinitis and chronic rhinosinusitis, with or without nasal polyps) was excluded owing to its high prevalence and limited discriminatory value in this cohort. Abbreviations: BMI, body mass index; FESS, functional endoscopic sinus surgery; GERD, gastroesophageal reflux disease; ICS, inhaled corticosteroid; LABA, long-acting β2-agonist; LAMA, long-acting muscarinic antagonist; LTRA, leukotriene receptor antagonist; NSAID, non-steroidal anti-inflammatory drug; SA, severe asthma; sIgE, specific immunoglobulin E; SPT, skin prick test. Table 2Clinical and Spirometric Outcomes According to Early Clinical Remission Status After 6 Months of Biologic TherapyParameterOverall (n=30)Early Clinical Remission (n=16)No Clinical Remission (n=14)p-valueACQ score at baseline3.09 ± 0.812.96 ± 0.643.14 ± 0.930.52Change in ACQ score from baseline−1.75 [−2.20, −1.03]−1.98 [−2.60, −1.78]−1.10 [−1.68, −0.91]0.01Mini-AQLQ score at baseline3.25 ± 1.013.33 ± 1.023.19 ± 0.970.69Change in mini-AQLQ score from baseline2.05 [1.13–2.75]2.15 [1.18–3.05]2.05 [1.08–2.25]0.31Cumulative OCS dose in the year prior to enrollment*1.23 [1.00–2.85]1.00 [0.88–1.34]2.20 [1.21–3.75]0.03Cumulative OCS dose during 6 months after treatment initiation0.00 [0.00–0.00]0.00 [0.00–0.00]0.00 [0.00–1.85]0.01OCS–treated exacerbations (previous year before enrollment)3.0 [2.0–4.0]2.5 [2.0–4.0]3.0 [3.0–4.0]0.12Any OCS-treated exacerbation during follow-up, n (%)4/30 (13.3)0/16 (0.0)4/14 (28.6)0.04Hospitalizations due to exacerbations in the year before enrollment0.0 [0.0–0.0]0 [0.0–0.0]0 [0.0–1.0]0.38Pre-bronchodilator FEV1, (%) predicted77.3 ± 17.980.3 ± 19.173.9 ± 16.50.33Change in pre-bronchodilator FEV1 (%), percentage points5.5 [1.25–19.0]15.0 [8–29]0.5 [−2.5–6.0]<0.01Pre-bronchodilator FEV1, L2.26 ± 0.802.37 ± 0.792.13 ± 0.810.41Change in pre-bronchodilator FEV1, L0.15 [0.04–0.42]0.35 [0.17–0.79]0.01 [−0.11–0.14]<0.001Pre-bronchodilator FVC, % predicted94.3 ± 15.796.4 ± 15.491.9 ± 16.30.66Change in pre-bronchodilator FVC (%), percentage points4.5 [−0.5–21.5]21.0 [4.0–26.3]2.5 [−6.3–9.5]<0.01Pre-bronchodilator FVC, L3.34 ± 0.933.43 ± 0.833.25 ± 1.050.44Change in pre-bronchodilator FVC, L0.15 [−0.02–0.55]0.55 [0.12–1.11]0.02 [−0.18–0.29]<0.01Notes: Data are presented as mean ± standard deviation, median [interquartile range], or n/N (%), as appropriate. P values refer to comparisons between the early clinical remission and no clinical remission groups. * Expressed as mg/day prednisone equivalent, averaged over the 12 months prior to enrollmentAbbreviations: ACQ, Asthma Control Questionnaire; mini-AQLQ, Mini Asthma Quality of Life Questionnaire; FEV1, forced expiratory volume in 1 second; FVC, forced vital capacity; OCS, oral corticosteroids. Clinical and Spirometric Outcomes According to Early Clinical Remission Status After 6 Months of Biologic Therapy Notes: Data are presented as mean ± standard deviation, median [interquartile range], or n/N (%), as appropriate. P values refer to comparisons between the early clinical remission and no clinical remission groups. * Expressed as mg/day prednisone equivalent, averaged over the 12 months prior to enrollment Abbreviations: ACQ, Asthma Control Questionnaire; mini-AQLQ, Mini Asthma Quality of Life Questionnaire; FEV1, forced expiratory volume in 1 second; FVC, forced vital capacity; OCS, oral corticosteroids. Primary Endpoint: Changes in Circulating Eosinophil-Related and Remodeling-Associated Biomarkers After 6 Months After 6 months of anti–IL-5/IL-5Rα therapy, the largest treatment-related changes were seen in eosinophil-related biomarkers. Blood eosinophil count fell from 325 [200–605] to 30 [0–58] cells/µL, with a median relative change of −95.3% [−100.0 to −85.5]. EDN decreased from 50.9 [32.71–84.62] to 7.0 [5.16–18.10] ng/mL, with a median relative change of −79.5% [−88.8 to −57.4], while CLC declined from 1.97 [1.25–2.96] to 1.32 [0.96–1.98] ng/mL, with a median relative change of −32.9% [−58.1 to −0.6]. All of these changes remained significant after FDR adjustment. Changes in remodeling-associated biomarkers were smaller and limited to selected analytes. Significant decreases were observed for MMP-10, which fell from 1603.4 [1535.9–1620.3] to 1519.1 [1367.18–1586.55] pg/mL, with a median relative change of −5.0% [−10.6 to −1.7], as well as for TGF-β1, which decreased from 27.77 [22.97–31.36] to 20.60 [17.08–22.75] ng/mL, with a median relative change of −21.2% [−31.8 to −12.1], and TGF-β2, which declined from 2.91 [2.47–3.70] to 2.54 [2.03–3.03] ng/mL, with a median relative change of −10.9% [−21.9 to −5.8]. By contrast, no significant group-level changes were observed for eotaxin-1, MMP-9, TIMP-1, fibulin-1, tenascin-C, or periostin (Table 3 and Figure 1).Table 3Changes in Circulating Eosinophil-Related and Remodeling-Associated Blood Biomarkers in the Overall Cohort After 6 Months of IL-5 Pathway InhibitionBiomarkerBaseline (V0)6 Months (V1)P valueFDR-Adjusted P valueEosinophil-related blood biomarkersEOS (cells/µL)325 [200–605]30 [0–58]<0.001<0.001EDN (ng/mL)50.9 [32.71–84.62]7.0 [5.16–18.10]<0.001<0.001Galectin-10 (ng/mL)1.97 [1.25–2.96]1.32 [0.96–1.98]0.0010.003Eotaxin-1 (pg/mL)73.48 [63.46–81.40]74.77 [62.41–84.63]0.8860.886Extracellular matrix- and remodeling-associated blood biomarkersMMP-10 (pg/mL)1603.4 [1535.9–1620.3]1519.1 [1367.18–1586.55]<0.0010.002MMP-9 (ng/mL)728.9 [586.40–792.31]625.6 [498.6–891.04]0.7460.820TIMP-1 (ng/mL)845.10 [769.80–892.31]819.5 [751.51–878.02]0.3290.602Fibulin-1 (ng/mL)863.21 [671.61–1055.72]882.6 [760.91–1016.12]0.5430.746Tenascin-C (ng/mL)10.37 [10.23–10.55]10.35 [10.23–10.50]0.6990.820Periostin (ng/mL)94.61 [73.01–109.80]92.42 [76.31–104.10]0.5430.746TGF-β1 (ng/mL)27.77 [22.97–31.36]20.60 [17.08–22.75]<0.001<0.001TGF-β2 (ng/mL)2.91 [2.47–3.70]2.54 [2.03–3.03]<0.0010.002Notes: Data are presented as median [interquartile range]. P values were calculated using the Wilcoxon signed-rank test. P values for the overall biomarker analysis were additionally adjusted using the Benjamini–Hochberg false discovery rate procedure (FDR).Abbreviations: EDN, eosinophil-derived neurotoxin; EOS, blood eosinophils; FDR, false discovery rate; MMP, matrix metalloproteinase; TIMP-1, tissue inhibitor of metalloproteinases-1; TGF-β, transforming growth factor beta. Figure 1Median relative changes in circulating biomarker concentrations after 6 months of IL-5 pathway inhibition in the overall cohort. Points represent median relative change from baseline, calculated as (V1 − V0)/V0 × 100, and horizontal lines indicate the interquartile range. Negative values indicate a decrease from baseline.A dot and whisker plot illustrates median percent changes from baseline with interquartile ranges for various analytes. The x-axis is labeled ′Median percent change from baseline (IQR)′ with ticks at -100, -75, -50, -25, 0, 25, 50 and 75 and a vertical dashed line at 0. The y-axis includes: Eotaxin-1 (CCL11), Fibulin-1, Tenascin-C, TIMP-1, MMP-9, Periostin, TGF-beta2, TGF-beta1, MMP-10, Galectin-10, EDN, Blood eosinophils. Medians and IQRs are: Eotaxin-1 (CCL11) 6.0, -30.5 to 18.1; Fibulin-1 2.0, -11.9 to 37.0; Tenascin-C 0.0, -1.9 to 1.6; TIMP-1 -2.2, -8.1 to 6.9; MMP-9 -7.6, -27.4 to 26.3; Periostin -14.2, -29.2 to 16.6; TGF-beta2 -10.9, -21.9 to -5.8; TGF-beta1 -21.2, -31.8 to -12.1; MMP-10 -5.0, -10.6 to -1.7; Galectin-10 -32.9, -58.1 to -0.6; EDN -79.5, -88.8 to -57.4; Blood eosinophils -95.3, -100.0 to -85.5.A dot and whisker plot of biomarker median percent change, with largest decreases in blood eosinophils and EDN.Abbreviations: EDN, eosinophil-derived neurotoxin; MMP, matrix metalloproteinase; TIMP-1, tissue inhibitor of metalloproteinases-1; TGF-β, transforming growth factor beta. Table 3Changes in Circulating Eosinophil-Related and Remodeling-Associated Blood Biomarkers in the Overall Cohort After 6 Months of IL-5 Pathway InhibitionBiomarkerBaseline (V0)6 Months (V1)P valueFDR-Adjusted P valueEosinophil-related blood biomarkersEOS (cells/µL)325 [200–605]30 [0–58]<0.001<0.001EDN (ng/mL)50.9 [32.71–84.62]7.0 [5.16–18.10]<0.001<0.001Galectin-10 (ng/mL)1.97 [1.25–2.96]1.32 [0.96–1.98]0.0010.003Eotaxin-1 (pg/mL)73.48 [63.46–81.40]74.77 [62.41–84.63]0.8860.886Extracellular matrix- and remodeling-associated blood biomarkersMMP-10 (pg/mL)1603.4 [1535.9–1620.3]1519.1 [1367.18–1586.55]<0.0010.002MMP-9 (ng/mL)728.9 [586.40–792.31]625.6 [498.6–891.04]0.7460.820TIMP-1 (ng/mL)845.10 [769.80–892.31]819.5 [751.51–878.02]0.3290.602Fibulin-1 (ng/mL)863.21 [671.61–1055.72]882.6 [760.91–1016.12]0.5430.746Tenascin-C (ng/mL)10.37 [10.23–10.55]10.35 [10.23–10.50]0.6990.820Periostin (ng/mL)94.61 [73.01–109.80]92.42 [76.31–104.10]0.5430.746TGF-β1 (ng/mL)27.77 [22.97–31.36]20.60 [17.08–22.75]<0.001<0.001TGF-β2 (ng/mL)2.91 [2.47–3.70]2.54 [2.03–3.03]<0.0010.002Notes: Data are presented as median [interquartile range]. P values were calculated using the Wilcoxon signed-rank test. P values for the overall biomarker analysis were additionally adjusted using the Benjamini–Hochberg false discovery rate procedure (FDR).Abbreviations: EDN, eosinophil-derived neurotoxin; EOS, blood eosinophils; FDR, false discovery rate; MMP, matrix metalloproteinase; TIMP-1, tissue inhibitor of metalloproteinases-1; TGF-β, transforming growth factor beta. Changes in Circulating Eosinophil-Related and Remodeling-Associated Blood Biomarkers in the Overall Cohort After 6 Months of IL-5 Pathway Inhibition Notes: Data are presented as median [interquartile range]. P values were calculated using the Wilcoxon signed-rank test. P values for the overall biomarker analysis were additionally adjusted using the Benjamini–Hochberg false discovery rate procedure (FDR). Abbreviations: EDN, eosinophil-derived neurotoxin; EOS, blood eosinophils; FDR, false discovery rate; MMP, matrix metalloproteinase; TIMP-1, tissue inhibitor of metalloproteinases-1; TGF-β, transforming growth factor beta. Median relative changes in circulating biomarker concentrations after 6 months of IL-5 pathway inhibition in the overall cohort. Points represent median relative change from baseline, calculated as (V1 − V0)/V0 × 100, and horizontal lines indicate the interquartile range. Negative values indicate a decrease from baseline. Key Secondary Endpoints: Clinical Outcomes at 6 Months In the overall cohort, within-patient comparisons showed substantial clinical improvement over the 6-month treatment period. Asthma control improved markedly, with a median change in ACQ score of −1.75 [−2.20 to −1.03] (p<0.01), and this was accompanied by a clinically relevant improvement in quality of life, reflected by a median increase in mini-AQLQ score of 2.05 [1.13–2.75] points (p<0.01). Lung function also improved, with median increases of 0.15 [0.04–0.42] L in pre-bronchodilator FEV1 (p<0.01) and 5.5 [1.25–19.0] percentage points in pre-bronchodilator FEV1 % predicted (p<0.001). Pre-bronchodilator FVC increased by 0.15 [−0.02–0.55] L (p<0.01) and by 4.5 [−0.5–21.5] percentage points (p<0.01). Exacerbation-related outcomes were also favorable during follow-up. Only 4 of 30 patients (13.3%) experienced at least one OCS-treated exacerbation, while cumulative OCS exposure remained 0.00 [0.00–0.00] in the overall cohort. Overall, these findings support a broad clinical benefit of anti–IL-5/IL-5Rα therapy after 6 months of treatment (Table 2). Key Secondary Endpoint: Study-Defined Early Clinical Remission Study-defined ECR at 6 months was achieved in 16 of 30 patients (53.3%). Compared with patients who did not achieve ECR, those in the ECR group had lower cumulative OCS exposure in the year prior to enrollment (1.00 [0.88–1.34] vs 2.20 [1.21–3.75], p=0.03) and a lower burden of selected comorbidities affecting asthma control (0.0 [0.0–1.0] vs 1.5 [0.25–2.75], p=0.03). Chronic heart failure was more frequent in the non-ECR group (50.0% vs 12.5%, p=0.046). During follow-up, patients achieving ECR showed greater improvement in asthma control and lung function, with a larger reduction in ACQ score (−1.98 [−2.60 to −1.78] vs −1.10 [−1.68 to −0.91], p=0.01) and greater improvement in pre-bronchodilator FEV1 in liters (0.35 [0.17–0.79] vs 0.01 [−0.11–0.14], p<0.001). Similar differences were observed for FEV1 % predicted and for FVC in both liters and percent predicted (Table 1 and Table 2). Exploratory Analyses: Biomarker Profile According to ECR Status At baseline, patients who achieved ECR tended to have higher eosinophilic inflammatory burden, with numerically higher blood eosinophil counts and eosinophil-related biomarker concentrations compared with the non-ECR group. This pattern was most pronounced for EDN, which showed a trend toward higher baseline concentrations in the ECR group (p=0.08), although the between-group difference did not reach statistical significance. During follow-up, reductions in circulating eosinophil-related and selected remodeling-related biomarkers were observed in both ECR and non-ECR groups. EDN and galectin-10 showed numerically greater decreases in the ECR group. Among remodeling-related biomarkers, MMP-10, TGF-β1, and TGF-β2 decreased in both groups, with comparable median changes between ECR and non-ECR patients. None of the between-group differences in 6-month biomarker changes reached statistical significance (Figure 2 and Supplementary Table 1). Figure 2Box-and-whisker plots with overlaid individual data points showing changes in blood eosinophil count and circulating biomarkers from baseline to month 6 in adult patients with severe eosinophilic asthma treated with anti–IL-5/IL-5Rα biologics. The analyzed parameters included: (A) plasma eosinophil-derived neurotoxin (EDN), (B) blood eosinophil count (EOS), and (C) serum concentrations of galectin-10, (D) transforming growth factor-β1 (TGF-β1), (E) transforming growth factor-β2 (TGF-β2), (F) matrix metalloproteinase-10 (MMP-10), (G) periostin, (H) matrix metalloproteinase-9 (MMP-9), (I) tissue inhibitor of metalloproteinases-1 (TIMP-1), (J) tenascin-C (TNC), (K) fibulin-1 (FBLN1), and (L) eotaxin-1. Results are presented separately for patients who achieved early clinical remission and those who did not. Boxes represent the median and interquartile range, whiskers indicate the range excluding outliers, and individual dots represent single-patient values. Within-group comparisons between baseline and month 6 were performed using the Wilcoxon signed-rank test.Twelve box-and-whisker plots display changes in circulating biomarkers from baseline to month 6, comparing early remission (n equals 16) and non-remission (n equals 14) groups. Each box represents the median and interquartile range, whiskers extend to the minimum and maximum excluding outliers and outliers are plotted as individual points visible in both groups across several panels. The x-axis in all plots shows two timepoints: baseline and month 6. Image A: y-axis shows plasma eosinophil-derived neurotoxin in nanograms per milliliter, ranging from 0 to 350. Medians decrease notably from baseline to month 6 in both groups; p less than 0.001 in both. Image B: y-axis shows blood eosinophil count in cells per microliter, ranging from 0 to 1200. Large decreases observed in both groups; p less than 0.001 in both. Image C: y-axis shows galectin-10 in nanograms per milliliter, ranging from 0 to 14. Modest decreases seen; p equals 0.016 in early remission and p equals 0.042 in non-remission. Image D: y-axis shows transforming growth factor beta 1 in nanograms per milliliter, ranging from 10 to 50. Decreases in both groups; p equals 0.002 and p equals 0.011. Image E: y-axis shows transforming growth factor beta 2 in nanograms per milliliter, ranging from 3 to 7. Decreases in both groups; p equals 0.009 and p equals 0.030. Image F: y-axis shows matrix metalloproteinase-10 in picograms per milliliter, ranging from 800 to 1900. Decreases in both groups; p equals 0.018 and p equals 0.005. Images G through L show periostin, matrix metalloproteinase-9, tissue inhibitor of metalloproteinases-1, tenascin-C, fibulin-1 and eotaxin-1 respectively, with no statistically significant changes in either group across all remaining panels.Biomarker levels in severe asthma: baseline vs 6 months for remission/non-remission groups. Box-and-whisker plots with overlaid individual data points showing changes in blood eosinophil count and circulating biomarkers from baseline to month 6 in adult patients with severe eosinophilic asthma treated with anti–IL-5/IL-5Rα biologics. The analyzed parameters included: (A) plasma eosinophil-derived neurotoxin (EDN), (B) blood eosinophil count (EOS), and (C) serum concentrations of galectin-10, (D) transforming growth factor-β1 (TGF-β1), (E) transforming growth factor-β2 (TGF-β2), (F) matrix metalloproteinase-10 (MMP-10), (G) periostin, (H) matrix metalloproteinase-9 (MMP-9), (I) tissue inhibitor of metalloproteinases-1 (TIMP-1), (J) tenascin-C (TNC), (K) fibulin-1 (FBLN1), and (L) eotaxin-1. Results are presented separately for patients who achieved early clinical remission and those who did not. Boxes represent the median and interquartile range, whiskers indicate the range excluding outliers, and individual dots represent single-patient values. Within-group comparisons between baseline and month 6 were performed using the Wilcoxon signed-rank test. Exploratory Analyses Comparisons by Biologic Type Exploratory comparisons between mepolizumab- and benralizumab-treated patients did not reveal consistent differences in clinical outcomes or biomarker changes (Supplementary Table 2). Correlations with Eosinophilic Parameters Among the analyzed blood biomarkers, only baseline EDN concentration correlated positively with blood eosinophil count at qualification (Spearman’s rho = 0.58, p = 0.0008), whereas no significant association was found with peak blood eosinophil count. Baseline TGF-β1 concentration showed a weak-to-moderate positive correlation with peak blood eosinophil count (rho = 0.37, p = 0.043), while only a non-significant trend was observed for eosinophil count at qualification (rho = 0.33, p = 0.076). No other biomarkers, including CLC and matrix- or remodeling-related markers, showed significant correlations with eosinophilic parameters (Supplementary Table 3A). Associations with Spirometric Parameters No significant correlations were identified between circulating biomarkers, including eosinophil-related, matrix-, and remodeling-related markers, and spirometric indices (Supplementary Table 3A). Associations with Comorbidity Burden A higher burden of relevant comorbidities was associated with lower baseline FEV1 and FVC expressed in liters (rho = −0.43, p = 0.018 and rho = −0.50, p = 0.005, respectively), whereas no significant associations were found for percent-predicted spirometric parameters. In addition, comorbidity burden correlated positively with annual OCS exposure (rho = 0.40, p = 0.029) and the number of exacerbations requiring OCS (rho = 0.48, p = 0.007) (Supplementary Table 3B). Discussion In this prospective real-world cohort of patients with severe eosinophilic asthma, IL-5 pathway inhibition with mepolizumab or benralizumab was associated with marked reductions in circulating eosinophil-related biomarkers after 6 months of treatment, accompanied by more selective changes in selected remodeling-related mediators. These biological effects occurred alongside substantial clinical improvement in asthma control, quality of life, lung function, and exacerbation-related outcomes. Although study-defined ECR was achieved in more than half of the patients, exploratory subgroup analyses showed that biomarker changes were broadly similar in the ECR and non-ECR groups, whereas remission itself was associated primarily with lower baseline OCS exposure and a lower comorbidity load. Within this overall pattern of biomarker suppression, the magnitude of change differed across eosinophil-related biomarkers. As expected, blood eosinophils showed the most pronounced reduction, reflecting the direct effect of IL-5/IL-5Rα blockade on eosinophil survival and depletion. EDN also declined markedly, consistent with its role as a soluble eosinophil-derived granule protein and marker of eosinophil activation.2 Notably, EDN correlated with blood eosinophil counts in our cohort, supporting its close relationship with circulating eosinophilic burden. In contrast, the smaller decline in galectin-10 and its lack of correlation with blood EOS in our cohort suggest that this marker may capture a partly distinct dimension of eosinophilic inflammation rather than simply track circulating eosinophil numbers. This may relate to the biology of galectin-10, which is associated with eosinophil cytolysis/ETosis and Charcot–Leyden crystal formation rather than classical granule release, and is not entirely eosinophil-specific. Previous studies indicate that sputum Gal-10 is closely associated with sputum eosinophilia, whereas blood associations appear less consistent.5,15 Eosinophils are an important source of TGF-β1 in eosinophilic asthma, and their depletion may therefore affect TGF-β signaling beyond the local airway compartment. In severe asthma, eosinophils are a major TGF-β–expressing cell population within the airway wall, and airway-based studies have linked eosinophilic inflammation with submucosal TGF-β expression and disease severity.16,17 Against this background, the reduction in serum TGF-β1 and TGF-β2 after IL-5 pathway inhibition in our cohort is consistent with the known biology of eosinophilic asthma and with previous reports, including studies in benralizumab-treated patients.18 This finding should, however, be interpreted with caution, because most evidence for reduced TGF-β after IL-5 pathway blockade comes from bronchoalveolar lavage fluid and bronchial biopsy studies rather than from blood-based measurements.19,20 In our cohort, serum TGF-β1 showed a weak-to-moderate association with peak eosinophil counts but not with baseline lung function. This may indicate that circulating TGF-β reflects the overall burden of eosinophilic inflammatory activity more than fixed structural airway changes. Previous studies have shown that TGF-β can be induced during allergen-driven airway inflammation and may reflect early inflammatory and reparative responses.21,22 Taken together, the observed reductions in circulating TGF-β may primarily reflect suppression of eosinophilic inflammation and related pro-remodeling signaling, rather than direct reversal of established airway remodeling. This interpretation is further supported by similar TGF-β reductions in the ECR and non-ECR groups despite greater functional improvement in the former. Interestingly, in REMOMEPO study, serum TGF-β1 showed heterogeneous kinetics between 6 and 12 months of mepolizumab treatment. This variability may partly relate to corticosteroid exposure in that cohort, as approximately half of the patients were on maintenance OCS and OCS treatment was modified during follow-up, potentially affecting circulating biomarker readouts. In contrast, chronic OCS use and recent systemic corticosteroid exposure were excluded in our study, which may have improved the interpretability of treatment-related blood biomarker changes.11 The modest but statistically significant decrease in serum MMP-10 observed in our study is best explained by its close association with eosinophilic airway inflammation, as MMP-10 expression has been linked to eosinophil-rich airway tissue, type-2 inflammatory signatures, and early extracellular matrix turnover rather than neutrophilic pathways.23,24 The smaller magnitude of MMP-10 reduction compared with that reported after tezepelumab therapy may suggest that MMP-10 expression is only partially dependent on the eosinophilic axis and may additionally be regulated by upstream type-2 inflammatory pathways beyond IL-5.25 In contrast, no significant group-level change in circulating MMP-9 was observed, consistent with its predominant association with neutrophil-driven inflammatory pathways.26,27 Not all remodeling-related biomarkers exhibited comparable kinetics. Tenascin-C showed minimal variation over time, whereas periostin, fibulin-1, MMP-9, and TIMP-1 displayed more heterogeneous individual trajectories, resulting in no significant group-level change. In contrast to the reductions observed for TGF-β1, TGF-β2, and MMP-10, this pattern suggests that IL-5 pathway inhibition does not affect all circulating remodeling-related markers uniformly. This interpretation is broadly consistent with airway-based studies showing that mepolizumab may reduce selected remodeling markers in bronchoalveolar lavage, including tenascin-C and fibulin-1, without equally clear changes in serum.11 Likewise, periostin appears to show compartment-dependent kinetics, with airway-derived reductions not consistently mirrored in blood.28,29 Overall, these findings suggest that blood-based remodeling biomarkers may only partly reflect localized airway remodeling processes. Study-defined ECR was achieved in 16 of 30 patients (53%) after 6 months of treatment. Although clinical remission in severe asthma is usually defined over 12 months, assessment at 6 months remains clinically relevant, as GINA recommends review of response to biologic therapy after approximately 3–6 months.1 Accordingly, our endpoint should be interpreted as an early multidimensional treatment milestone rather than definitive long-term remission. Importantly, patients who achieved ECR showed significantly greater improvement in asthma control and lung function, including a larger reduction in ACQ score and greater gains in pre-bronchodilator FEV1 and FVC, both in liters and percent predicted. In our cohort, however, ECR appeared to be associated more with baseline clinical burden than with a clearly distinct blood biomarker profile. Patients who achieved ECR had lower prior OCS exposure and a lower burden of comorbidities affecting asthma control, while chronic heart failure was more frequent in the non-ECR group. Moreover, in the overall cohort, a higher comorbidity burden correlated with both the number of OCS-treated exacerbations and cumulative OCS exposure, further supporting its clinical relevance. Among eosinophil-related biomarkers, EDN appeared closest to differentiating remission from non-remission at baseline, although this did not reach statistical significance (p=0.08). Given the small size of our subgroup analysis, this trend should be interpreted cautiously, but it may still indicate a biological signal, particularly in light of recent data linking EDN with response to biologic therapy in severe asthma.30,31 By contrast, 6-month changes in eosinophil-related and remodeling-associated biomarkers were broadly similar in the ECR and non-ECR group. Overall, these findings should be interpreted cautiously, but suggest that non-ECR in our cohort was more closely related to broader clinical burden than to absent biological response, in keeping with recent reports showing that remission is more likely in patients with lower disease burden, less OCS dependence, and fewer comorbidities.9,32 In exploratory analyses, mepolizumab and benralizumab were associated with a broadly similar pattern of clinical benefit and biomarker change. While our sample size does not allow firm conclusions regarding comparative effectiveness, this observation suggests that the main findings of the study reflect a class-related effect of IL-5 pathway inhibition rather than a signal confined to a single biologic. This study has several limitations. The single-center design and modest sample size limit generalizability and constrain statistical power, particularly for exploratory subgroup analyses by remission status and biologic type. The observational nature of the study and the absence of a placebo-controlled comparator group preclude definitive causal inference regarding treatment-related effects. Therefore, we cannot fully exclude that some observed biomarker changes may have been influenced by spontaneous variability, regression to the mean, or other time-dependent factors unrelated to IL-5 pathway inhibition. In addition, comparisons between mepolizumab and benralizumab were exploratory and should not be interpreted as robust comparative effectiveness analyses. Furthermore, the 6-month follow-up captures an early treatment phase rather than established long-term remission, while blood-based biomarkers cannot directly characterize local airway remodeling or account for spatial heterogeneity within the airways. Notwithstanding these limitations, the study has notable strengths. To our knowledge, it is among the first prospective real-world analyses to combine multidimensional clinical outcomes with a broad panel of eosinophil-related and remodeling-associated circulating biomarkers in severe eosinophilic asthma during IL-5 pathway inhibition. A particular strength is the deliberate reduction of major sources of biomarker confounding at baseline, including maintenance OCS use, recent exacerbations, acute infection, and systemic immunosuppressive therapy. This design feature enhances the interpretability of the blood biomarker data and supports the biological relevance of the observed treatment-related changes. Conclusion IL-5 pathway inhibition in a severe eosinophilic asthma cohort was associated with strong suppression of circulating eosinophil-related biomarkers and more selective modulation of remodeling-associated mediators, alongside meaningful clinical benefit after 6 months. Biomarker changes did not differ significantly between patients with and without early clinical remission; however, this exploratory finding should be interpreted cautiously given baseline clinical differences between groups. These observations suggest that incomplete clinical response may, at least in part, reflect broader disease burden, including comorbidities, rather than insufficient suppression of eosinophilic inflammation alone. Larger prospective studies with longer follow-up are needed to establish whether these changes are sustained and whether they reflect true disease modification.